-
Lycia Therapeutics Lands $106M for Protein Degraders That Treat Autoimmune & Inflammatory Diseases
13 May 2024 15:21 GMT
… medication adherence and health outcomes.
Lycia has one big pharmaceutical … -1 drugs currently used to treat obesity. … Pharmaceuticals drug candidate vimseltinib. SynOx’s drug was originally discovered and developed … Keytruda for the treatment of advanced solid …
-
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
13 May 2024 12:00 GMT
… in the US despite current treatment options,” said Ronald Martell … half of 2025. This trial, along with our ongoing … clinical-stage biotechnology company developing briquilimab, a monoclonal antibody … cell disease (SCD), Fanconi anemia (FA) and severe combined …
-
Ajax, aiming for a better JAK drug, raises $95M to begin first tests
13 May 2024 14:19 GMT
… the pharmaceutical industry. Several are approved to treat inflammatory … search for better immunological drugs.
Ajax Therapeutics, … trial. That study will test a drug, codenamed AJ1-11095, Ajax is developing … leading to symptoms like anemia and fatigue. Though …
-
Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
13 May 2024 13:06 GMT
… infusion and regularly throughout treatment. If triglyceride levels … , patent ductus arteriosus, anemia, gastroesophageal reflux disease, … existing products; product development risks; inability to … : The Need for Pharmacist Intervention. Nutr Clin Pract …
-
Ajax Therapeutics Announces FDA Clearance of IND Application for AJ1-11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis
13 May 2024 11:17 GMT
… U.S. Food and Drug Administration (FDA) to initiate a … was developed to provide a much-needed new treatment for … in the bone marrow, progressive anemia, and debilitating symptoms, such … progression, leaving significant unmet treatment needs for these patients. …
-
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
13 May 2024 11:01 GMT
… committed to the development of new treatment options for … #47;Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic … the impact of pharmaceutical industry regulation and health … _pi.pdf and Medication Guide for KEYTRUDA at …
-
Why Does White Hair Not Return To Its Original Colour After Turning Grey?
13 May 2024 11:42 GMT
There is a lot of misinformation and myths associated with getting back your natural hair colour once it begins to turn grey or white
It is normal for your hair to change its original colour from white or grey with the loss of melanin - a pigment-producing …
-
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
10 May 2024 20:48 GMT
… treatment option across multiple cancers.
Opdivo’s leading global development … Food and Drug Administration (FDA) approved Yervoy … 47;immune): hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis ( … and Ono Pharmaceutical Collaboration
In …
-
FDA Grants Fast Track Designation to SNB-101 in Small Cell Lung Cancer
10 May 2024 17:18 GMT
… the fast track designation, developers may apply for the … a phase 1 trial (NCT04640480) evaluating treatment with SNB-101 … granted orphan drug designation to the agent for treating patients with … the safety, tolerability, and pharmacokinetics of SNB-101 (SN- …
-
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
10 May 2024 10:14 GMT
… When compared with pre-treatment history, data showed … .S. Food and Drug Administration (FDA) who has set … mutations.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: … that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte …